Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

338.48 +4.08 (+1.22%)
Streaming Delayed Price Updated: 12:48 PM EDT, Sep 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BeOne Medicines Ltd. - American Depositary Shares

< Previous 1 2 Next >
Analyst Expectations For BeOne Medicines's Future
 
Via Benzinga
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio?
These ten large-cap stocks were top performers last week. Are they a part of your portfolio? 
Via Benzinga
A Glimpse of BeiGene's Earnings Potential
 
Via Benzinga
Earnings Scheduled For August 6, 2025
 
Via Benzinga
BeiGene's Earnings: A Preview
 
Via Benzinga
Earnings Preview: BeiGene
 
Via Benzinga
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients
BeOne Medicines reported positive Phase 1/2 results for sonrotoclax in relapsed or refractory mantle cell lymphoma, with regulatory submissions underway and a Phase 3 trial in progress. 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Affirm Posts Better-Than-Expected Earnings, Joins Ambarella, IREN, Petco Health and Wellness And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen. 
Via Benzinga
Earnings Scheduled For August 8, 2025
 
Via Benzinga
BeOne Medicines (ONC) Q2 EPS Soars 924%
Via The Motley Fool
Deep Dive Into BeOne Medicines Stock: Analyst Perspectives (9 Ratings)
 
Via Benzinga
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
Via Benzinga
What 8 Analyst Ratings Have To Say About BeOne Medicines
 
Via Benzinga
AppLovin, First Solar And Li Auto Are Among Top 10 Large Cap Losers Last Week (June 16-20): Are The Others In Your Portfolio?
Top 10 worst performing large-cap stocks last week: APP, FSLR, JHX, ONC, GSK, ACN, ANET, LI, CPAY, MA. Reasons include short-sell report, tax bill, and market selloff. 
Via Benzinga
CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Topics Economy Law Enforcement
Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat
BeiGene posted a surprise Q1 profit and $1.12 billion in revenue, with strong U.S. Brukinsa sales, while reaffirming its 2025 outlook and margin guidance. 
Via Benzinga
Earnings Scheduled For May 14, 2025
 
Via Benzinga
Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial
The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy. 
Via Stocktwits
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway. 
Via Benzinga
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Forecasting The Future: 4 Analyst Projections For BeiGene
 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.